DK1549353T3 - Anvendelse af alfa(1,3)galactosyltransferaseudtrykkende allogene tumorceller til vaccination mod tumorer - Google Patents

Anvendelse af alfa(1,3)galactosyltransferaseudtrykkende allogene tumorceller til vaccination mod tumorer

Info

Publication number
DK1549353T3
DK1549353T3 DK03779090.4T DK03779090T DK1549353T3 DK 1549353 T3 DK1549353 T3 DK 1549353T3 DK 03779090 T DK03779090 T DK 03779090T DK 1549353 T3 DK1549353 T3 DK 1549353T3
Authority
DK
Denmark
Prior art keywords
cells
tumor
tumor cells
galactosyltransferase
alpha
Prior art date
Application number
DK03779090.4T
Other languages
English (en)
Inventor
Charles J Link Jr
Tatiana Seregina
Gabriela Rossi
Original Assignee
Central Iowa Health System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Central Iowa Health System filed Critical Central Iowa Health System
Application granted granted Critical
Publication of DK1549353T3 publication Critical patent/DK1549353T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0271Chimeric vertebrates, e.g. comprising exogenous cells
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57Skin; melanoma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4611T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • A61K39/464454Enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • A61K39/46449Melanoma antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/0331Animal model for proliferative diseases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5152Tumor cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Environmental Sciences (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK03779090.4T 2002-10-09 2003-10-09 Anvendelse af alfa(1,3)galactosyltransferaseudtrykkende allogene tumorceller til vaccination mod tumorer DK1549353T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41734302P 2002-10-09 2002-10-09
PCT/US2003/032036 WO2004032865A2 (en) 2002-10-09 2003-10-09 Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase

Publications (1)

Publication Number Publication Date
DK1549353T3 true DK1549353T3 (da) 2010-07-12

Family

ID=32094006

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03779090.4T DK1549353T3 (da) 2002-10-09 2003-10-09 Anvendelse af alfa(1,3)galactosyltransferaseudtrykkende allogene tumorceller til vaccination mod tumorer

Country Status (13)

Country Link
US (5) US20040191229A1 (da)
EP (1) EP1549353B1 (da)
JP (1) JP4966496B2 (da)
CN (2) CN1756568A (da)
AT (1) ATE462449T1 (da)
AU (1) AU2003285863A1 (da)
CA (1) CA2501744C (da)
DE (1) DE60331933D1 (da)
DK (1) DK1549353T3 (da)
ES (1) ES2341335T3 (da)
HK (1) HK1215044A1 (da)
MX (1) MXPA05003705A (da)
WO (1) WO2004032865A2 (da)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1054683B1 (en) 1998-02-20 2007-04-11 University Of Miami Modified heat shock protein-antigenic peptide complex
US20050201993A1 (en) * 2002-10-09 2005-09-15 Link Charles J.Jr. Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase
MXPA05003705A (es) 2002-10-09 2005-08-16 Central Iowa Health System Vacunacion antitumoral usando celulas de tumor alogeneico que expresan alfa (1,3)-galactosil transferasa.
CN101052709B (zh) * 2004-10-25 2012-06-27 贝勒研究院 装载热激黑素瘤细胞体的树突细胞
US7820628B2 (en) * 2005-02-22 2010-10-26 University Of Massachusetts Medical School Tumor lesion regression and conversion in situ into autologous tumor vaccines by compositions that result in anti-Gal antibody binding
US7713266B2 (en) 2005-05-20 2010-05-11 Myoscience, Inc. Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat)
US7850683B2 (en) * 2005-05-20 2010-12-14 Myoscience, Inc. Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat)
US7998486B2 (en) 2006-10-25 2011-08-16 Newlink Genetics Corporation Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes
US9254162B2 (en) 2006-12-21 2016-02-09 Myoscience, Inc. Dermal and transdermal cryogenic microprobe systems
US8409185B2 (en) 2007-02-16 2013-04-02 Myoscience, Inc. Replaceable and/or easily removable needle systems for dermal and transdermal cryogenic remodeling
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
WO2009065061A1 (en) 2007-11-14 2009-05-22 Myoscience, Inc. Pain management using cryogenic remodeling
US20100112702A1 (en) * 2008-02-25 2010-05-06 Klein Benjamin Y Method designed to divert glucose away from the glycolytic pathway
DK2257301T3 (da) 2008-03-03 2014-04-28 Univ Miami Immunterapi baseret på allogene cancerceller.
WO2009117116A2 (en) 2008-03-20 2009-09-24 University Of Miami Heat shock protein gp96 vaccination and methods of using same
JP2012503471A (ja) * 2008-05-30 2012-02-09 グライコフィ, インコーポレイテッド 末端アルファ−1,3−結合ガラクトースを有するタンパク質の製造のための酵母株
CN102223894A (zh) * 2008-11-21 2011-10-19 迈阿密大学 用于产生粘膜和系统免疫的hiv/siv疫苗
ES2427980T3 (es) 2008-12-22 2013-11-05 Myoscience, Inc. Sistema crioquirúrgico integrado con refrigerante y fuente de energía eléctrica
CN102695807B (zh) * 2009-11-10 2016-02-24 雀巢产品技术援助有限公司 心脏衰老生物标志物及其用途
US20110150934A1 (en) * 2009-12-18 2011-06-23 University Of Notre Dame Ovarian Tumor Tissue Cell Preparations/Vaccines for the Treatment/Inhibition of Ovarian Tumors and Ovarian Cancer
WO2011079070A1 (en) * 2009-12-23 2011-06-30 Gradalis, Inc. Furin-knockdown bi-functional rna
SG10201606680QA (en) 2009-12-23 2016-10-28 Gradalis Inc Furin-knockdown and gm-csf-augmented (fang) cancer vaccine
CN102711794B (zh) * 2010-01-04 2015-11-25 Kj生物科学有限公司 用于疫苗和诊断学的Dps融合蛋白
CN102286428A (zh) * 2011-06-04 2011-12-21 内蒙古医学院 一种在肿瘤细胞表面合成α-半乳糖苷表位并激活免疫细胞的方法
CN102716497A (zh) * 2011-07-07 2012-10-10 赵永祥 α1,3半乳糖基转移酶基因转染材料及其制备方法和应用
EP2802279B1 (en) 2012-01-13 2017-08-16 Myoscience, Inc. Cryogenic needle with freeze zone regulation
CA2860893A1 (en) 2012-01-13 2013-07-18 Myoscience, Inc. Skin protection for subdermal cryogenic remodeling for cosmetic and other treatments
CA2861116A1 (en) 2012-01-13 2013-07-18 Myoscience, Inc. Cryogenic probe filtration system
US9017318B2 (en) 2012-01-20 2015-04-28 Myoscience, Inc. Cryogenic probe system and method
CN102760208B (zh) * 2012-07-03 2015-07-29 清华大学 基于模拟疫苗的动态人工免疫故障诊断方法
WO2014064534A2 (en) 2012-10-05 2014-05-01 Chrontech Pharma Ab Injection needle, device, immunogenic compositions and method of use
US9295512B2 (en) 2013-03-15 2016-03-29 Myoscience, Inc. Methods and devices for pain management
US20160022826A1 (en) * 2013-03-15 2016-01-28 Newlink Genetics Corporation Carbohydrate-modified glycoproteins and uses thereof
WO2014146127A1 (en) 2013-03-15 2014-09-18 Myoscience, Inc. Methods and systems for treatment of spasticity
US20140350536A1 (en) 2013-03-15 2014-11-27 Myoscience, Inc. Cryogenic Blunt Dissection Methods and Devices
US9610112B2 (en) 2013-03-15 2017-04-04 Myoscience, Inc. Cryogenic enhancement of joint function, alleviation of joint stiffness and/or alleviation of pain associated with osteoarthritis
EP2996716A4 (en) * 2013-05-15 2017-01-25 Newlink Genetics Corporation Correlates of efficacy relating to tumor vaccines
WO2015069792A1 (en) 2013-11-05 2015-05-14 Myoscience, Inc. Secure cryosurgical treatment system
ES2845727T3 (es) 2015-02-06 2021-07-27 Heat Biologics Inc Vector que coexpresa una vacuna y moléculas coestimuladoras
GB201505860D0 (en) * 2015-04-07 2015-05-20 Agalimmune Ltd Therapeutic compositions and methods of use for treating cancer
EP3454762B1 (en) 2016-05-13 2024-04-03 Pacira CryoTech, Inc. Systems for locating and treating with cold therapy
CA3040123A1 (en) 2016-10-11 2018-04-19 University Of Miami Vectors and vaccine cells for immunity against zika virus
US11548930B2 (en) 2017-04-04 2023-01-10 Heat Biologics, Inc. Intratumoral vaccination
US11896653B2 (en) 2017-09-13 2024-02-13 Unm Rainforest Innovations Silicified cell replicas, methods of making, and methods of using
EP3709918A4 (en) 2017-11-15 2021-08-11 Pacira CryoTech, Inc. INTEGRATED COLD THERAPY AND ELECTRIC STIMULATION SYSTEMS FOR LOCALIZATION AND TREATMENT OF NERVE AND RELATED PROCEDURES
US20220282220A1 (en) * 2019-07-24 2022-09-08 Sl Bigen Inc. Method for preparation of immortalized stem cell line and use thereof
TW202134430A (zh) 2019-12-03 2021-09-16 美商紐沃進公司 腫瘤細胞疫苗
WO2021139810A1 (en) * 2020-01-10 2021-07-15 The University Of Hong Kong Recombinant viruses expressing alpha-1, 3-galactosyltransferase and uses thereof
US20230149456A1 (en) * 2020-03-30 2023-05-18 Unm Rainforest Innovations Nanoparticle-loaded silicified cells, methods of making, and methods of use
WO2022256360A1 (en) * 2021-06-02 2022-12-08 Neuvogen, Inc. Tumor cell vaccines

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5879675A (en) * 1994-03-15 1999-03-09 Medical College Of Pennsylvania And Hahnemann University Compositions and methods for vaccines comprising α-galactosyl epitopes
US6218166B1 (en) * 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods
JP2001517206A (ja) * 1996-08-16 2001-10-02 ザ ジョンズ ホプキンズ ユニヴァーシティ スクール オヴ メディシン 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法
US5869035A (en) * 1996-11-13 1999-02-09 Human Gene Therapy Research Institute Methods and compositions for inducing complement destruction of tissue
EP1119365A4 (en) * 1997-07-24 2003-08-13 Univ Jefferson COMPOSITIONS AND METHODS FOR USING TUMOR CELLS
US7005126B1 (en) * 1999-06-08 2006-02-28 Human Gene Therapy Research Institute Method for tumor treatment using infusion of xenogeneic cells to induce hyperacute rejection and innocent bystander effect
US7101543B2 (en) * 2000-03-31 2006-09-05 Novarx Genetically modified cells expressing a TGFβ inhibitor, the cells being lung cancer cells
AU2002235141A1 (en) * 2000-11-27 2002-06-03 Geron Corporation Glycosyltransferase vectors for treating cancer
US20050201993A1 (en) * 2002-10-09 2005-09-15 Link Charles J.Jr. Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase
MXPA05003705A (es) 2002-10-09 2005-08-16 Central Iowa Health System Vacunacion antitumoral usando celulas de tumor alogeneico que expresan alfa (1,3)-galactosil transferasa.

Also Published As

Publication number Publication date
EP1549353A2 (en) 2005-07-06
US20110250233A1 (en) 2011-10-13
US20070014775A1 (en) 2007-01-18
WO2004032865A2 (en) 2004-04-22
US9474801B2 (en) 2016-10-25
ES2341335T3 (es) 2010-06-18
US20040191229A1 (en) 2004-09-30
JP2006507267A (ja) 2006-03-02
US20140037692A1 (en) 2014-02-06
CN1756568A (zh) 2006-04-05
EP1549353B1 (en) 2010-03-31
US7763461B2 (en) 2010-07-27
CN104911210A (zh) 2015-09-16
WO2004032865A3 (en) 2004-06-10
US8535658B2 (en) 2013-09-17
CA2501744C (en) 2012-01-03
AU2003285863A8 (en) 2004-05-04
AU2003285863A1 (en) 2004-05-04
MXPA05003705A (es) 2005-08-16
US20070014774A1 (en) 2007-01-18
DE60331933D1 (de) 2010-05-12
CA2501744A1 (en) 2004-04-22
HK1215044A1 (zh) 2016-08-12
ATE462449T1 (de) 2010-04-15
WO2004032865A9 (en) 2004-07-22
JP4966496B2 (ja) 2012-07-04

Similar Documents

Publication Publication Date Title
DK1549353T3 (da) Anvendelse af alfa(1,3)galactosyltransferaseudtrykkende allogene tumorceller til vaccination mod tumorer
Weiner et al. Genetic vaccines
JP2023133525A (ja) がん及び感染症の治療方法並びに治療用組成物
WO2008057235A3 (en) Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
CY1113394T1 (el) Αντισωματα toy pan-kir2dl νκ υποδοχεα και η χρηση τους στη διαγνωση και τη θεραπεια
TW200602077A (en) Compositions as adjuvants to improve immune responses to vaccines and methods of use
TW200513280A (en) Microprojection array immunization patch and method
CN102149391A (zh) 用于治疗肿瘤疾病的组合物和方法
CN105899217A (zh) 癌症疗法中的番木瓜花叶病毒和病毒样颗粒
ATE521629T1 (de) Matrixmetalloproteinase-11-impfstoff
Noh et al. GM-CSF-loaded chitosan hydrogel as an immunoadjuvant enhances antigen-specific immune responses with reduced toxicity
CA3018308A1 (en) Treatment of cancer using recall antigens delivered by attenuated bacteria
DE69434244D1 (de) Verbesserte krebstherapie
IL173481A0 (en) Polysaccharide double-layer microcapsules as carriers for biologically active substance oral administration
CN106456730A (zh) 用于诱导或延长细胞之细胞毒性免疫应答的方法的药物
CN105007930B (zh) 用于治疗疾病的同种异体自噬体富集组合物
de Jesus Jimenez-Chavez et al. Therapy with multi-epitope virus-like particles of B19 parvovirus reduce tumor growth and lung metastasis in an aggressive breast cancer mouse model
DE60137146D1 (de) Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
EP1556513A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES MEDIATED BY THE HUMANE PAPILLOMA VIRUS
Macedo et al. Intra-cheek immunization as a novel vaccination route for therapeutic vaccines of head and neck squamous cell carcinomas using plasmo virus-like particles
Ye et al. rWTC-MBTA: autologous vaccine prevents metastases via antitumor immune responses
ES2635516T3 (es) Sensibilización para vacunación con TH1 para inmunoterapia activa
Gupta et al. Periodontal vaccine: A new vista in periodontology-A review
Ye et al. Targeting DNA vaccines to myeloid cells using a small peptide